Aurinia Pharmaceuticals AUPH Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's additional paid-in capital?
- Aurinia Pharmaceuticals (AUPH) reported additional paid-in capital of $96.87M in Q1 2026.
- How has Aurinia Pharmaceuticals's additional paid-in capital changed year-over-year?
- Aurinia Pharmaceuticals's additional paid-in capital decreased by 4.1% year-over-year, from $100.98M to $96.87M.
- What is the long-term trend for Aurinia Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's additional paid-in capital has grown at a 23.1% compound annual growth rate (CAGR), from $39.38M to $111.26M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.